Neko Health raises $700M Series C for U.S. expansion
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Neko Health raised a $700 million Series C led by Lightspeed Venture Partners and O.G. Venture Partners, following its $260 million Series B closed in January 2025.
- Neko Health pairs proprietary body-scanning hardware with bloodwork and can integrate Apple Health data, giving its medical clinicians real-world context in assessments, per co-founder Hjalmar Nilsonne.
- Neko Health currently operates in the UK and Sweden, is preparing its first U.S. location in New York, and has scanned more than 100,000 people, with another 350,000 on its waitlist or with scheduled appointments.
- The scan now includes body composition data targeted at gym-goers, expanding beyond the company's original preventative health-assessment focus.
- Alex Tew, founder of Calm, said a Neko Health scan detected a malignant mole on his back that he subsequently had removed, writing on X that he was unsure how he would have found it otherwise.
- Other investors in the round include Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD.
- MidJourney is also building a body scanner planned to open inside a San Francisco spa with hot tubs and saunas in 2027, underscoring growing competition in consumer body-scanning.
Why it matters: Neko Health's $700M round gives the Spotify-founder-backed startup the capital to open its first U.S. clinic in New York after scanning 100,000+ people in Europe. MidJourney — best known for AI image generation — entering the same space with a 2027 San Francisco spa concept shows consumer preventative scanning is attracting capital from well outside traditional healthcare.
